Dr. David Greenberg outlines bladder cancer staging, BCG, immunotherapy, surgery, quality of life impacts and long-term ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
SurvivorNet on MSN
Inlexzo: A new option for bladder cancer patients when BCG immunotherapy stops working
If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your ...
A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
SurvivorNet on MSN
After A Bladder Cancer Diagnosis At 39, Groundbreaking New Treatment Option Inlexzo Allows Texas Man To Avoid Surgery & Get Back To An Active Life
Jimi Stewart, a rollerblading enthusiast from Austin, Texas, was diagnosed with a type of non-muscle invasive bladder cancer ...
A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results